Horizon Investment Services LLC Boosts Position in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX)

Horizon Investment Services LLC boosted its position in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX - Free Report) by 167.1% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 39,524 shares of the biopharmaceutical company's stock after purchasing an additional 24,724 shares during the period. Horizon Investment Services LLC's holdings in Catalyst Pharmaceuticals were worth $825,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors have also added to or reduced their stakes in the company. Pictet Asset Management Holding SA grew its holdings in shares of Catalyst Pharmaceuticals by 27.4% in the fourth quarter. Pictet Asset Management Holding SA now owns 15,969 shares of the biopharmaceutical company's stock worth $333,000 after purchasing an additional 3,431 shares during the last quarter. Norges Bank bought a new position in Catalyst Pharmaceuticals in the 4th quarter worth about $1,915,000. JPMorgan Chase & Co. increased its position in shares of Catalyst Pharmaceuticals by 80.3% during the fourth quarter. JPMorgan Chase & Co. now owns 736,197 shares of the biopharmaceutical company's stock worth $15,364,000 after acquiring an additional 327,936 shares during the period. Segall Bryant & Hamill LLC raised its stake in shares of Catalyst Pharmaceuticals by 97.8% during the fourth quarter. Segall Bryant & Hamill LLC now owns 80,354 shares of the biopharmaceutical company's stock valued at $1,677,000 after acquiring an additional 39,721 shares in the last quarter. Finally, Prudential Financial Inc. raised its stake in shares of Catalyst Pharmaceuticals by 30.2% during the fourth quarter. Prudential Financial Inc. now owns 553,424 shares of the biopharmaceutical company's stock valued at $11,550,000 after acquiring an additional 128,525 shares in the last quarter. Institutional investors own 79.22% of the company's stock.

Remove Ads

Catalyst Pharmaceuticals Price Performance

Shares of CPRX stock traded down $0.34 during mid-day trading on Tuesday, hitting $23.91. 888,162 shares of the stock traded hands, compared to its average volume of 1,114,832. The stock's fifty day moving average is $22.69 and its two-hundred day moving average is $21.86. Catalyst Pharmaceuticals, Inc. has a 52-week low of $14.47 and a 52-week high of $26.16. The stock has a market cap of $2.90 billion, a P/E ratio of 20.27, a P/E/G ratio of 3.31 and a beta of 0.84.

Wall Street Analyst Weigh In

Several research firms have commented on CPRX. StockNews.com upgraded Catalyst Pharmaceuticals from a "buy" rating to a "strong-buy" rating in a report on Friday, February 28th. Robert W. Baird increased their price target on Catalyst Pharmaceuticals from $28.00 to $32.00 and gave the stock an "outperform" rating in a research report on Monday, March 3rd. Bank of America reaffirmed a "buy" rating and issued a $30.00 price objective on shares of Catalyst Pharmaceuticals in a research note on Thursday, January 9th. Stephens reiterated an "overweight" rating and set a $33.00 target price on shares of Catalyst Pharmaceuticals in a report on Thursday, February 27th. Finally, Baird R W upgraded shares of Catalyst Pharmaceuticals to a "strong-buy" rating in a report on Monday, February 3rd. Seven equities research analysts have rated the stock with a buy rating and two have issued a strong buy rating to the company. According to data from MarketBeat, the company currently has a consensus rating of "Buy" and an average target price of $32.29.

Insider Activity at Catalyst Pharmaceuticals

In other Catalyst Pharmaceuticals news, insider Brian Elsbernd sold 62,975 shares of the business's stock in a transaction that occurred on Monday, March 3rd. The shares were sold at an average price of $22.98, for a total transaction of $1,447,165.50. Following the sale, the insider now owns 188,564 shares of the company's stock, valued at approximately $4,333,200.72. The trade was a 25.04 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, insider Gary Ingenito sold 44,904 shares of the firm's stock in a transaction on Wednesday, March 5th. The stock was sold at an average price of $22.09, for a total transaction of $991,929.36. Following the completion of the transaction, the insider now directly owns 68,873 shares of the company's stock, valued at approximately $1,521,404.57. This represents a 39.47 % decrease in their position. The disclosure for this sale can be found here. 11.00% of the stock is currently owned by corporate insiders.

Catalyst Pharmaceuticals Company Profile

Catalyst Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients.